Small-cap stock under ₹50 in focus as board sets date to consider fundraising proposal
Blue Cloud Softech Solutions has scheduled a board meeting for Wednesday, May 7, 2025, to evaluate fundraising options and to discuss possible acquisitions both in India and internationally.
'Raising of funds by way of issuance of equity shares/convertible warrants including but not limited to through preferential issue and/ or Qualified Institutions Placement (QIP)/ or any other methods on private placement basis, through one or more permissible modes or issue of securities in any combination thereof etc. subject to regulatory approvals, as may be required,' said the company in its exchange filing.
Blue Cloud Softech Solutions stated in its exchange filing that the board may also consider holding an extraordinary general meeting or a postal ballot to obtain the shareholders' approval for the previously mentioned proposal, if necessary.
Blue Cloud Softech Solutions specialises in the design, development, and marketing of computer software both in India and internationally, as well as offering various data processing services, which include computer consultancy, systems analysis, and programming and computer maintenance in India or abroad.
Blue Cloud Softech Solutions has recently obtained a work order from Pinnacle Hospitals India Pvt Ltd to deploy its state-of-the-art Outpatient Management System (OMS) at Pinnacle Hospitals in Visakhapatnam.
Additionally, the company revealed the successful completion of a notable US$ 3.20 million agreement to deliver its domestically developed AI-driven healthcare management solution, the BluHealth Comprehensive Healthcare Platform, to a distinguished client based in the United States.
Blue Cloud Softech Solutions shares experienced a drop of 1.79% on Wednesday's session, the stock touched an intraday high of ₹ 17.11 apiece, and an intraday low of ₹ 16.32 per share on the BSE. Over the last week, the stock declined by 2.71%. It has decreased by 58.50% over the past three months and has fallen 62.51% in the previous year.
Disclaimer: The views and recommendations above are those of individual analysts, experts and broking companies, not of Mint. We advise investors to check with certified experts before making any investment decision.
First Published: 1 May 2025, 10:17 AM IST
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 hours ago
- Time of India
‘Ensures financial independence': Vietnam bride gets unusual dowry; gift includes 100 civet cats
AI-generated image A 22-year-old Vietnamese bride received a bizarre dowry featuring 100 civet cats and substantial wealth in various forms, with her father claiming it will ensure her financial independence. The wedding, which took place last May in southwestern Vietnam but recently reported by the South China Morning Post, saw the bride receive breeding-capable female civet cats valued at 1.8 billion Vietnamese dong (US$70,000). H er parents' endowment also encompassed 25 taels of gold, 500 million dong (US$20,000) in cash, corporate shares worth 300 million dong, seven properties and additional valuable items. The groom's family reciprocated by gifting the bride price of 10 taels of gold, 200 million dong in cash and diamond ornaments. In many Asian societies, dowries continue to serve as a significant custom, claiming to be a representation of familial prosperity and parental support for their daughter's future. Hong Chi Tam, the bride's father, explained that his children manage the family enterprise after their university education. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like This Device Made My Power Bill Drop Overnight elecTrick - Save upto 80% on Power Bill Pre-Order Undo He aimed to provide his daughter with income-generating assets. He expressed support for his daughter's autonomy in deciding whether to maintain or sell the civet cats. "My daughter is a business school graduate. She is fully capable of managing these assets. No matter the method, it ensures her financial independence," Hong said. In Vietnam, civet cats represent a significant investment opportunity. A female civet that has reproduced can sell for approximately 18 million dong (US$700), whilst expecting females command up to 27 million dong. These animals are particularly valuable for their contribution to Kopi Luwak coffee production, amongst the world's costliest coffee varieties. The process involves the civets consuming coffee cherries, with the beans later collected from their droppings, sanitised, processed and roasted. Civet meat is considered a delicacy in China and Vietnam, with additional uses in traditional Chinese medicine. World Animal Protection International reports that civets are frequently captured from their natural habitat using harmful traps. They are subsequently sold to farms where poor conditions and stress lead to self-harm and premature death.
Economic Times
3 hours ago
- Economic Times
KKR-backed IVI to buy ART Fertility Clinics for $450 million
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel KKR-backed IVI RMA Global, a US-based leader in infertility treatment, is set to acquire ART Fertility Clinics for $400-450 million, according to people familiar with the matter. The acquisition marks a significant step in IVI RMA's global expansion, adding India to its presence in over 15 countries and more than 190 clinical offices across the US, Europe and Latin parties are in the final stages of documentation for a shareholders' agreement and are hoping to wrap up the transaction by June with private hospitals, the IVF industry in India too is witnessing consolidation as several private equity funds have been aggressive with acquisitions. In 2023, Swedish fund EQT Partners acquired a significant majority stake in Indira IVF, the largest provider of fertility services in India and top five globally in terms of annual IVF cycles, at a $1.1 billion ('9,000 crore) Fertility Clinics began in 2015 as IVI Middle East, an international arm of IVI RMA Global. In 2020, IVI RMA divested the business to Gulf Capital, which rebranded it as ART Fertility Clinics. Since then, the brand has rapidly grown, expanding across West Asia and clinics in Abu Dhabi, Dubai and Al Ain in the UAE as well as 11 centres across India, ART Fertility has established itself as a high-performance network in reproductive medicine. The Indian expansion began in 2021, backed by a $30 million investment from Gulf Fertility operates in big Indian cities including Mumbai, Noida, Ahmedabad, Chennai, Hyderabad, Gurgaon and by Suresh Soni, former co-founder and CEO of Nova IVF Fertility, ART Fertility reports a pregnancy success rate of 70% and has recorded over 5,000 successful pregnancies in under nine to sources, ART Fertility posted revenue of $100-120 million in FY25, with an estimated Ebitda of $35 million."For an Indian healthcare player, a $25-35 million ebitda which is borderline ebitda positive coming from the Middle East would add no value," said a fund manager at a Mumbai-based private equity firm that operates a pan-India IVF chain. "However, IVI being a US player where multiples are low, adding a Middle East business works well."IVI RMA trumped a rival bid by Temasek-backed Cloudnine Hospitals.A KKR spokesperson declined to comment. IVI RMA and ART Fertility did not respond to is the advisor in the is rapidly emerging as one of the world's fastest-growing markets for Assisted Reproductive Technology (ART). However, the sector has scope for expansion at 210 IVF cycles per million people, compared with 1,200 in the US and over 2,000 in affects approximately 15% of Indian couples, a figure expected to rise due to lifestyle factors such as poor diet, stress, late marriages, and to EY, India's IVF market is expected to grow from $793 million in 2020 to $1.45 billion by 2027, at a projected CAGR of 15-20%.India sees around 300,000 IVF cycles annually, with projections suggesting this could grow to 500,000-600,000 cycles by 2030. About 30% of the market is controlled by 10-15 organised players, while the remaining is fragmented among smaller, unorganised clinics. Key players in India's fertility sector include Indira IVF, Nova IVF, Oasis IVF, Bloom Fertility Centre, Bengaluru-based Milann, Morpheus IVF, Ridge IVF, Akanksha IVF and Bourn Hall IVF, the second largest player in India, is owned by Asia Healthcare Holdings (AHH), the single specialty hospitals platform backed by GIC and homegrown PE fund Kedaara Capital owns a minority stake in Oasis Fertility, while Brussels-based fund Verlinvest owns a controlling stake in Ferty9 F, a premier chain of fertility clinics in the AP/Telangana region.
Time of India
4 hours ago
- Time of India
KKR-backed IVI to buy ART Fertility Clinics for $450 million
KKR-backed IVI RMA Global, a US-based leader in infertility treatment, is set to acquire ART Fertility Clinics for $400-450 million, according to people familiar with the matter. The acquisition marks a significant step in IVI RMA's global expansion, adding India to its presence in over 15 countries and more than 190 clinical offices across the US, Europe and Latin America. Both parties are in the final stages of documentation for a shareholders' agreement and are hoping to wrap up the transaction by June end. As with private hospitals, the IVF industry in India too is witnessing consolidation as several private equity funds have been aggressive with acquisitions. In 2023, Swedish fund EQT Partners acquired a significant majority stake in Indira IVF, the largest provider of fertility services in India and top five globally in terms of annual IVF cycles, at a $1.1 billion ('9,000 crore) valuation. ART Fertility Clinics began in 2015 as IVI Middle East, an international arm of IVI RMA Global. In 2020, IVI RMA divested the business to Gulf Capital, which rebranded it as ART Fertility Clinics. Since then, the brand has rapidly grown, expanding across West Asia and India. Live Events With clinics in Abu Dhabi, Dubai and Al Ain in the UAE as well as 11 centres across India, ART Fertility has established itself as a high-performance network in reproductive medicine. The Indian expansion began in 2021, backed by a $30 million investment from Gulf Capital. ART Fertility operates in big Indian cities including Mumbai, Noida, Ahmedabad, Chennai, Hyderabad, Gurgaon and Faridabad. Led by Suresh Soni, former co-founder and CEO of Nova IVF Fertility, ART Fertility reports a pregnancy success rate of 70% and has recorded over 5,000 successful pregnancies in under nine years. According to sources, ART Fertility posted revenue of $100-120 million in FY25, with an estimated Ebitda of $35 million. "For an Indian healthcare player, a $25-35 million ebitda which is borderline ebitda positive coming from the Middle East would add no value," said a fund manager at a Mumbai-based private equity firm that operates a pan-India IVF chain. "However, IVI being a US player where multiples are low, adding a Middle East business works well." IVI RMA trumped a rival bid by Temasek-backed Cloudnine Hospitals. A KKR spokesperson declined to comment. IVI RMA and ART Fertility did not respond to queries. Moelis is the advisor in the transaction. India is rapidly emerging as one of the world's fastest-growing markets for Assisted Reproductive Technology (ART). However, the sector has scope for expansion at 210 IVF cycles per million people, compared with 1,200 in the US and over 2,000 in Europe. Infertility affects approximately 15% of Indian couples, a figure expected to rise due to lifestyle factors such as poor diet, stress, late marriages, and pollution. According to EY, India's IVF market is expected to grow from $793 million in 2020 to $1.45 billion by 2027, at a projected CAGR of 15-20%. India sees around 300,000 IVF cycles annually, with projections suggesting this could grow to 500,000-600,000 cycles by 2030. About 30% of the market is controlled by 10-15 organised players, while the remaining is fragmented among smaller, unorganised clinics. Key players in India's fertility sector include Indira IVF, Nova IVF, Oasis IVF, Bloom Fertility Centre, Bengaluru-based Milann, Morpheus IVF, Ridge IVF, Akanksha IVF and Bourn Hall Clinic. Nova IVF, the second largest player in India, is owned by Asia Healthcare Holdings (AHH), the single specialty hospitals platform backed by GIC and TPG. Similarly, homegrown PE fund Kedaara Capital owns a minority stake in Oasis Fertility, while Brussels-based fund Verlinvest owns a controlling stake in Ferty9 F, a premier chain of fertility clinics in the AP/Telangana region.
